erythromycin has been researched along with n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barford, JM; Bolton, VJ; Brown, SL; Cluff, C; Fell, SC; Jarvie, EM; Johnson, CN; Lawless, K; MacPherson, DT; Mahmood, SR; Matthews, KL; McKay, F; Mitchell, DJ; Mohamed, S; Muir, AI; Myatt, JW; Sanger, GJ; Seal, JT; Smith, B; Stanway, SJ; Stemp, G; Stevens, AJ; Thompson, M; Westaway, SM | 1 |
| Barnes, AA; Bolton, VN; Borman, RA; Cellek, S; Hellström, PM; Jarvie, EM; Lee, K; Macpherson, DT; Matthews, KL; Muir, AI; Näslund, E; Sanger, GJ; Unsworth, WP; Westaway, SM | 1 |
2 other study(ies) available for erythromycin and n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine
| Article | Year |
|---|---|
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
Topics: Animals; Dogs; Drug Discovery; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Muscle Contraction; Piperazines; Piperidines; Pyloric Antrum; Rabbits; Rats; Receptors, Gastrointestinal Hormone; Receptors, Neuropeptide | 2009 |
GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.
Topics: Animals; Defecation; Electric Stimulation; Erythromycin; Gallbladder Emptying; Gastrointestinal Motility; Humans; In Vitro Techniques; Male; Motilin; Parasympathetic Nervous System; Piperazines; Piperidines; Pyloric Antrum; Rabbits; Receptors, Gastrointestinal Hormone; Receptors, Neuropeptide; Recombinant Proteins; Stimulation, Chemical; Substrate Specificity | 2009 |